• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

聚焦于大麻素 1 型受体激动剂正变构调节剂 2-苯基吲哚骨架的结构-活性关系研究:具有增强活性和溶解度的 III 型芳环同系物。

Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility.

机构信息

Department of Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, MA 02115, United States.

Department of Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, MA 02115, United States; Health Sciences Entrepreneurs, Northeastern University, Boston, MA 02115, United States.

出版信息

Bioorg Med Chem. 2020 Nov 1;28(21):115727. doi: 10.1016/j.bmc.2020.115727. Epub 2020 Aug 29.

DOI:10.1016/j.bmc.2020.115727
PMID:33065437
Abstract

Specific tuning of cannabinoid 1 receptor (CB1R) activity by small-molecule allosteric modulators is a therapeutic modality with multiple properties inherently advantageous to therapeutic applications. We previously generated a library of unique CB1R positive allosteric modulators (PAMs) derived from GAT211, which has three pharmacophoric sites critical to its ago-PAM activity. To elaborate our CB1R PAM library, we report the rational design and molecular-pharmacology profiling of several 2-phenylindole analogs modified at the "site-III" aromatic ring. The comprehensive structure-activity relationship (SAR) investigation demonstrates that attaching small lipophilic functional groups on the ortho-position of the GAT211 site-III phenyl ring could markedly enhance CB1R ago-PAM activity. Select site-III modifications also improved GAT211's water solubility. The SAR reported both extends the structural diversity of this compound class and demonstrates the utility of GAT211's site-III for improving the parent compound's drug-like properties of potency and/or aqueous solubility.

摘要

通过小分子变构调节剂对大麻素 1 型受体 (CB1R) 活性进行特异性调节是一种具有多种固有优势的治疗模式,有利于治疗应用。我们之前从 GAT211 中生成了一组独特的 CB1R 正变构调节剂 (PAMs) 文库,该文库具有三个对其前激动剂活性至关重要的药效基团。为了详细说明我们的 CB1R PAM 文库,我们报告了几种在“位点 III”芳环上修饰的 2-苯基吲哚类似物的合理设计和分子药理学特征。全面的构效关系 (SAR) 研究表明,在 GAT211 位点 III 苯基环的邻位上连接小的亲脂性官能团可以显著增强 CB1R 前激动剂活性。对位点 III 的选择性修饰还提高了 GAT211 的水溶性。所报道的 SAR 不仅扩展了该化合物类别的结构多样性,还证明了 GAT211 位点 III 可用于改善母体化合物的药效性质,如效力和/或水溶解度。

相似文献

1
Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility.聚焦于大麻素 1 型受体激动剂正变构调节剂 2-苯基吲哚骨架的结构-活性关系研究:具有增强活性和溶解度的 III 型芳环同系物。
Bioorg Med Chem. 2020 Nov 1;28(21):115727. doi: 10.1016/j.bmc.2020.115727. Epub 2020 Aug 29.
2
Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure.大麻素1受体变构调节剂的设计、合成及药理学分析:C2组GAT211同系物降低眼压的临床前疗效
Bioorg Med Chem. 2021 Nov 15;50:116421. doi: 10.1016/j.bmc.2021.116421. Epub 2021 Sep 25.
3
Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.大麻素1受体的对映体特异性变构调节
ACS Chem Neurosci. 2017 Jun 21;8(6):1188-1203. doi: 10.1021/acschemneuro.6b00310. Epub 2017 Feb 7.
4
Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators.氟氮步行方法的应用:定义 2-苯基吲哚类大麻素 1 型受体正变构调节剂的结构和功能多样性。
J Med Chem. 2020 Jan 23;63(2):542-568. doi: 10.1021/acs.jmedchem.9b01142. Epub 2020 Jan 3.
5
Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy.大麻素 1 型受体别构调节剂的发现:抗青光眼的临床前疗效。
J Med Chem. 2021 Jun 24;64(12):8104-8126. doi: 10.1021/acs.jmedchem.1c00040. Epub 2021 Apr 7.
6
Multiple Binding Sites Contribute to the Mechanism of Mixed Agonistic and Positive Allosteric Modulators of the Cannabinoid CB1 Receptor.多个结合位点有助于大麻素 CB1 受体的混合激动剂和正变构调节剂的作用机制。
Angew Chem Int Ed Engl. 2018 Mar 1;57(10):2580-2585. doi: 10.1002/anie.201708764. Epub 2018 Feb 2.
7
Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.绘制大麻素1受体变构位点:新型、强效且不可逆结合探针GAT100的关键分子决定因素和信号特征
ACS Chem Neurosci. 2016 Jun 15;7(6):776-98. doi: 10.1021/acschemneuro.6b00041. Epub 2016 Apr 25.
8
Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.1 型大麻素受体的正变构调节可减轻 R6/2 小鼠模型亨廷顿病的症状和体征。
Neuropharmacology. 2019 Jun;151:1-12. doi: 10.1016/j.neuropharm.2019.03.033. Epub 2019 Mar 30.
9
The future of type 1 cannabinoid receptor allosteric ligands.1 型大麻素受体变构配体的未来。
Drug Metab Rev. 2018 Feb;50(1):14-25. doi: 10.1080/03602532.2018.1428341. Epub 2018 Jan 21.
10
Allosteric modulators restore orthosteric agonist binding to mutated CB receptors.变构调节剂恢复了突变 CB 受体的正构激动剂结合。
J Pharm Pharmacol. 2020 Jan;72(1):84-91. doi: 10.1111/jphp.13193. Epub 2019 Nov 13.

引用本文的文献

1
Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1.基于结构的大麻素受体 CB1 的 G 蛋白偏向性变构调节剂的鉴定。
Proc Natl Acad Sci U S A. 2024 Jun 11;121(24):e2321532121. doi: 10.1073/pnas.2321532121. Epub 2024 Jun 3.
2
In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1-indole (ZCZ011) at the Type 1 Cannabinoid Receptor: Allosteric Agonist or Allosteric Modulator?6-甲基-3-(2-硝基-1-(噻吩-2-基)乙基)-2-苯基-1-吲哚(ZCZ011)在1型大麻素受体上的体外特性研究:变构激动剂还是变构调节剂?
ACS Pharmacol Transl Sci. 2022 Nov 22;5(12):1279-1291. doi: 10.1021/acsptsci.2c00160. eCollection 2022 Dec 9.